Bayer joins transparency push

Share this article:

Bayer HealthCare has joined the transparency movement. The drugmaker is the latest to announce that it, too, was making de-identified clinical trial information available to approved researchers. Boehringer Ingelheim announced a similar policy earlier this week.

Bayer said in a statement that its decision is in support of the European Medicines Agency's efforts to increase access to clinical trial data, and noted that “as a member of the pharmaceutical trade associations EFPIA and PhRMA, Bayer is following their declared principles on responsible clinical trial data sharing.”

As with BI, an independent panel will grant or deny data access.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.